

CLAIM LISTING

Claims 1-23 (Cancelled)

24. (Currently Amended) A preparation for stimulating or enhancing an immune system, comprising a liquid food product or a drink comprising zinc, at least one agent selected from the group consisting of chlorogenic acid and functional analogs thereof, said agent stimulating T-lymphocytes *in vivo*, and at least one polysaccharide selected from the group consisting of β -1,3-glucans, arabinogalactans, and polysaccharides that induce interferon production which are isolated from *Echinacea* species, *Thuja occidentalis*, *Panax ginseng*, ~~fungi~~, *Aranica montana* cell cultures, *Plantago spp*, *Achyrocline satureioides*, *Aconitum officinalis*, *Angelica acutiloba*, *Aristolochia officinalis*, *Astragalus gummerifa*, *A. membranaceus*, *A. mongholicus*, *Avena sativa*, *Banbusa vulgaris*, *Baptista tinctoria*, *Bryonia dioica*, *Calendula officinalis*, *Carthamus tinctorius*, *Chamomilla recutita*, *Echinacea angustifolia*, *E. pallida*, *E. purpurea*, *Eleutherococcus senticosus*, *Eupatorium cannabinum*, *Silene vulgaris*, *Triticum sativum*, *Vincetoxicum officinalis*, and *Viscum album*,

wherein the weight to weight ratio of chlorogenic acid and functional analogs thereof to zinc is in the range of 0.0025 to 500.

25. (Cancelled)

26. (Cancelled)

27. (Previously Presented) A preparation according to claim 24, wherein the arabinogalactan is selected from the group consisting of arabinogalactans from *Baptista tinctoria*, *Echinacea* species, *Larix occidentalis* and *Angelica acutiloba*.

28. (Previously Presented) A preparation according to claim 24, wherein the zinc is present in an effective amount to be capable of inducing the production of interferon-gamma *in vivo*.

29. (Cancelled)

30. (Previously Presented) A preparation according to claim 24, wherein said ratio is in the range of 0.0025 to 2.5.

31. (Previously Presented) A preparation according to claim 30, wherein said ratio is in the range of 0.5 to 2.5.

32. (Previously Presented) A preparation according to claim 24, wherein said ratio is in the range of 0.5 to 500.

33. (Previously Presented) A preparation according to claim 24 comprising: (i) 10-200 mg of chlorogenic acid and/or functional analogs thereof and (ii) 1-200 mg zinc.


34. (Previously Presented) A preparation according to claim 24, wherein the zinc is included as an inorganic zinc salt

35. (Previously Presented) A preparation according to claim 34, wherein the zinc salt is selected from the group consisting of zinc carbonate, zinc sulfate, zinc oxide, zinc chloride and mixtures thereof.

36. (Previously Presented) A preparation according to claim 34, wherein the zinc salt is included as zinc citrate.


37. (Previously Presented) A preparation according to claim 24, wherein said functional analog is selected from the group consisting of chlorogenic acid, 4-caffeoylquinic acid, 5-caffeoylquinic acid and 1,5-dicaffeoylquinic acid, an isochlorogenic acid, 3,4,5 tricaffeoyl quinic acid, 1-O-caffeoylquinic acid, 1,3-O-caffeoylquinic acid), 1,3,4,5-O-tetracaffeoylquinic acid and 5-O-caffeoylshikimic acid.

38. (Previously Presented) A preparation according to claim 24, wherein said agent is a compound represented by formula 1,



(Formula 1)

wherein “a” represents either a single bond or a double bond, and R₁ is only present in case “a” represents a single bond, and wherein at least one of the functional groups R₁-R₄ represents a functional group represented by formula 2



(Formula 2)

and the remaining of said functional groups R₁-R₄ are independently chosen from the group formed by -OH and caffeic acid analogs abundant in a material of a vegetable nature.

39. (Previously Presented) A preparation according to claim 24, wherein said agent originates from one or more plants.

40. (Previously Presented) A preparation according to claim 39, wherein said plant is selected from the group consisting of *Echinacea sp.*, *Panax Ginseng*, green coffee bean, green cacao bean, hawthorn, green tea, elder tree, artichoke, guarana, butterbur, Phoenix spp, *Butia capitata*, Dandelion, a dicotylus *Compositae* or other dicotylus, *Arnica montana*, Birch tree and combinations thereof.

41. (Previously Presented) A preparation according to claim 24, further comprising at least one component, other than zinc and polysaccharides, which is capable of inducing the production of interferon-gamma.

42. (Previously Presented) A preparation according to claim 41, wherein said at least one component is N-acetylcysteine.

43. (Previously Presented) A preparation according to claim 24, further comprising at least one additive selected from the group consisting of ginsenosides, antioxidants, trace elements, lipoic acids, L-carnitines, minerals, vitamins, immuno-stimulants, anti-tumor agents and *Astragalus membranaceus* extracts.

44. (Previously Presented) A preparation according to claim 43, wherein the antioxidant is chosen from the group consisting of ascorbic acid, α -tocopherol and combinations thereof.

45. (Previously Presented) A preparation according to claim 43, wherein the trace element is chosen from the group consisting of manganese ions, copper ions, selenium ions, selenium compounds and combinations thereof.

46. (Previously Presented) A preparation according to claim 24, comprising at least one component in the specified amount, selected from the group consisting of 50-2000 mg N-acetylcystein, 200-2000 mg *Echinacea premium*, 0.2-150 mg ginsenosides, 2-200 mg beta glucans, 10-1000 mg ascorbic acid, 1-1000 mg α -tocopherol, 0.1-20 mg copper, 0,005-0.3 mg selenium, 1-100 mg lipoic acid, 10-2000 mg L-carnitine, and *Astragalus membranaceus* extract of 200-20000 mg dry material.

47. (Currently Amended) A preparation according to claim 24, wherein the liquid food product or drink is in the form of a ~~capsule, a tablet, a lozenge, a powder, an agglomerate, a paste, solution, a liquid, a gel,~~ an emulsion, a suspension, ~~a bar, a drink,~~ a lemonade, a fruit juice, or a dairy drink, ~~a pudding, an ice cream or a sauce.~~

48. (Cancelled)

49. (Withdrawn) A method for treatment and/or prophylaxis of cancer, comprising the use of a preparation according to claim 24.

50. (Withdrawn) A method according to claim 49, wherein zinc is used in an effective amount to induce the production of interferon-gamma.

51. (Withdrawn) A method for treatment and/or prophylaxis of an infection by an infectant, comprising the use of a preparation according to claim 24.

52. (Withdrawn) A method according to claim 51, wherein the infectant is selected from parasites, toxins, viruses, bacteria and combinations thereof.

53. (Withdrawn) A method according to claim 52, wherein the infectant is selected from the group of *Pox-viridae*, *Herpes-viridae*, *Adenoviridae*, *Papavoviridae*, *Hepadnaviridae*, *Parvoviridae*, *Reo-viridae*, *Picornaviridae*, *Toga-viridae*, *Flavi-viridae*, *Corona-viridae*, *Rhabdo-viridae*, *Paramyxo-viridae*, *Orthomixo-viridae*, *Filo-viridae*, *Bunya-viridae*, *Arena-viridae*, *Calici-viridae*, *Retroviridae*, *Papilloma*, *influenza*, HIV, HTLV, Corona, Eppstein Barr, *pneumococci*, *staphylococcus aureus* and combinations thereof.

54. (Withdrawn) A method according to claim 51, wherein the zinc is used in an effective amount to induce the production of interferon-gamma.

55. (Withdrawn) A method for stimulating T-lymphocytes comprising administering a preparation according to claim 24.

56. (Withdrawn) A method according to claim 55, wherein zinc is used in an effective amount to induce the production of interferon-gamma.

57. (Withdrawn) A method according to claim 55, wherein the method is part of a prophylactic or treatment protocol for cancer.

58. (Withdrawn) A method for preparing a product for stimulating T-lymphocytes, comprising the use of a preparation according to claim 24.

59. (Withdrawn) A vaccine comprising chlorogenic acid or a functional analog thereof as adjuvant, said vaccine further comprising zinc.

60. (Currently Amended) A food product or drink for stimulating or enhancing an immune system, comprising 1-200 mg of zinc, 0.5-500 mg of at least one agent selected from the group consisting of chlorogenic acid and functional analogs thereof, said agent stimulating T-lymphocytes *in vivo*, and at least one polysaccharide selected from the group consisting of β -1,3-glucans, arabinogalactans, and polysaccharides that induce interfereon production which are isolated from *Echinacea* species, *Thuja occidentalis*, *Panax ginseng*, ~~fungi~~, *Aranica montana* cell cultures, *Plantago spp*, *Achyrocline satureioides*, *Aconitum officinalis*, *Angelica acutiloba*, *Aristolochia officinalis*, *Astragalus gummerifa*, *A. membranaceus*, *A. mongholicus*, *Avena sativa*, *Banbusa vulgaris*, *Baptista tinctoria*, *Bryonia dioica*, *Calendula officinalis*, *Carthamus tinctorius*, *Chamomilla recutita*, *Echinacea angustifolia*, *E. pallida*, *E. purpurea*, *Eleutherococcus senticosus*, *Eupatorium cannabrinum*, *Silene vulgaris*, *Triticum sativum*, *Vincetoxicum officinalis*, and *Viscum album*,

wherein the food product or drink is a liquid ~~daily dose of chlorogenic acid and functional analogs thereof is 0.5-500 mg, and the daily dose of zinc is 1-200 mg.~~

61. (Currently Amended) A food product or drink according to claim 60, further comprising 50-2000 mg of N-acetylcysteine, and 2-300 mg of at least one agent selected from the group consisting of chlorogenic acid and functional analogs thereof ~~wherein the daily dose of N-acetylcysteine is 50-2000 mg and the daily dose of chlorogenic acid and functional analogs thereof is 2-300 mg.~~

62. (Previously Presented) A preparation according to claim 24, wherein the β -1,3-glucan is selected from the group consisting of β -1,3-glucans from the mushrooms *Lentinus edodes* (lentinan), *Schizophyllum commune* (schizophyllan), *Phytophthora parasytica*, *Grifola frondosa*, *Sclerotinia clerotiorum*, *Ganoderma lucidum*, *Coriolus versicolor* (krestin), and from the plants *Morinda citrifolia* fruit and *Viscum Album*.